165 related articles for article (PubMed ID: 7753998)
1. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose.
Steinert HC; Huch Böni RA; Buck A; Böni R; Berthold T; Marincek B; Burg G; von Schulthess GK
Radiology; 1995 Jun; 195(3):705-9. PubMed ID: 7753998
[TBL] [Abstract][Full Text] [Related]
2. Planar coincidence scintigraphy and PET in staging malignant melanoma.
Steinert HC; Voellmy DR; Trachsel C; Bicik I; Buck A; Huch RA; von Schulthess GK
J Nucl Med; 1998 Nov; 39(11):1892-7. PubMed ID: 9829578
[TBL] [Abstract][Full Text] [Related]
3. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose.
Böni R; Böni RA; Steinert H; Burg G; Buck A; Marincek B; Berthold T; Dummer R; Voellmy D; Ballmer B
Br J Dermatol; 1995 Apr; 132(4):556-62. PubMed ID: 7748746
[TBL] [Abstract][Full Text] [Related]
4. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma.
Gritters LS; Francis IR; Zasadny KR; Wahl RL
J Nucl Med; 1993 Sep; 34(9):1420-7. PubMed ID: 8355058
[TBL] [Abstract][Full Text] [Related]
5. Whole body positron emission tomography/computed tomography staging of metastatic choroidal melanoma.
Kurli M; Reddy S; Tena LB; Pavlick AC; Finger PT
Am J Ophthalmol; 2005 Aug; 140(2):193-9. PubMed ID: 15992753
[TBL] [Abstract][Full Text] [Related]
6. The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making.
Gulec SA; Faries MB; Lee CC; Kirgan D; Glass C; Morton DL; Essner R
Clin Nucl Med; 2003 Dec; 28(12):961-5. PubMed ID: 14663316
[TBL] [Abstract][Full Text] [Related]
7. Whole-body F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography imaging in the follow-up of metastatic uveal melanoma.
Klingenstein A; Haug AR; Nentwich MM; Tiling R; Schaller UC
Melanoma Res; 2010 Dec; 20(6):511-6. PubMed ID: 20890225
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of positron emission tomography for the detection of melanoma metastases.
Holder WD; White RL; Zuger JH; Easton EJ; Greene FL
Ann Surg; 1998 May; 227(5):764-9; discussion 769-71. PubMed ID: 9605668
[TBL] [Abstract][Full Text] [Related]
9. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma.
Eigtved A; Andersson AP; Dahlstrøm K; Rabøl A; Jensen M; Holm S; Sørensen SS; Drzewiecki KT; Højgaard L; Friberg L
Eur J Nucl Med; 2000 Jan; 27(1):70-5. PubMed ID: 10654150
[TBL] [Abstract][Full Text] [Related]
10. 2-Deoxy-2-[F-18]fluoro-D-glucose positron emission tomography/computed tomography in the management of melanoma.
Iagaru A; Quon A; Johnson D; Gambhir SS; McDougall IR
Mol Imaging Biol; 2007; 9(1):50-7. PubMed ID: 17051322
[TBL] [Abstract][Full Text] [Related]
11. Detection of malignancies with SPECT versus PET, with 2-[fluorine-18]fluoro-2-deoxy-D-glucose.
Martin WH; Delbeke D; Patton JA; Sandler MP
Radiology; 1996 Jan; 198(1):225-31. PubMed ID: 8539384
[TBL] [Abstract][Full Text] [Related]
12. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose.
Hoh CK; Hawkins RA; Glaspy JA; Dahlbom M; Tse NY; Hoffman EJ; Schiepers C; Choi Y; Rege S; Nitzsche E
J Comput Assist Tomogr; 1993; 17(4):582-9. PubMed ID: 8331230
[TBL] [Abstract][Full Text] [Related]
13. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients.
Rinne D; Baum RP; Hör G; Kaufmann R
Cancer; 1998 May; 82(9):1664-71. PubMed ID: 9576286
[TBL] [Abstract][Full Text] [Related]
14. Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma.
Wagner JD; Schauwecker D; Hutchins G; Coleman JJ
J Surg Oncol; 1997 Mar; 64(3):181-9. PubMed ID: 9121147
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography in the detection and management of metastatic melanoma.
Damian DL; Fulham MJ; Thompson E; Thompson JF
Melanoma Res; 1996 Aug; 6(4):325-9. PubMed ID: 8873053
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography scanning in malignant melanoma.
Tyler DS; Onaitis M; Kherani A; Hata A; Nicholson E; Keogan M; Fisher S; Coleman E; Seigler HF
Cancer; 2000 Sep; 89(5):1019-25. PubMed ID: 10964332
[TBL] [Abstract][Full Text] [Related]
17. Preoperative staging of liver metastases from uveal melanoma by magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography (FDG-PET).
Servois V; Mariani P; Malhaire C; Petras S; Piperno-Neumann S; Plancher C; Levy-Gabriel C; Lumbroso-le Rouic L; Desjardins L; Salmon RJ
Eur J Surg Oncol; 2010 Feb; 36(2):189-94. PubMed ID: 19775851
[TBL] [Abstract][Full Text] [Related]
18. Detection of metastatic lesions from malignant pheochromocytoma and paraganglioma with diffusion-weighted magnetic resonance imaging: comparison with 18F-FDG positron emission tomography and 123I-MIBG scintigraphy.
Takano A; Oriuchi N; Tsushima Y; Taketomi-Takahashi A; Nakajima T; Arisaka Y; Higuchi T; Amanuma M; Endo K
Ann Nucl Med; 2008 Jun; 22(5):395-401. PubMed ID: 18600417
[TBL] [Abstract][Full Text] [Related]
19. "One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases?
Heusner T; Gölitz P; Hamami M; Eberhardt W; Esser S; Forsting M; Bockisch A; Antoch G
Eur J Radiol; 2011 Jun; 78(3):430-5. PubMed ID: 19945240
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography and ultrasonography. A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma.
Blessing C; Feine U; Geiger L; Carl M; Rassner G; Fierlbeck G
Arch Dermatol; 1995 Dec; 131(12):1394-8. PubMed ID: 7492127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
